Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Hypertension ; 11(3): 282-4, 1988 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-3350589

RESUMEN

The mean of rapidly repeated duplicate or triplicate measurements is often used in studies of antihypertensive drugs. Forty patients with hypertension had triplicate measurements of blood pressure and heart rate on two occasions, 1 week apart, during placebo treatment. The average difference between the first measurement and the mean of the triplicate measurements was -0.3 mm Hg. The average coefficient of variation for supine and standing, systolic and diastolic blood pressures was 8.4% for the single measurements and 8.0% for the mean of triplicate measurements. The correlations between the first measurements and the mean of triplicate measurements ranged from 0.90 to 0.98 (all p less than 0.01). The average difference between the two visits for all four blood pressure parameters was -0.6 mm Hg for the single measurements and -0.5 mm Hg for the mean of triplicate measurements (all p = NS). These results indicate that 1) blood pressure does not change further after 1 week of placebo treatment, and 2) use of the mean of triplicate measurements of blood pressure and heart rate gives the same result as use of single measurements, and the results are no less variable.


Asunto(s)
Determinación de la Presión Sanguínea/métodos , Frecuencia Cardíaca , Hipertensión/diagnóstico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo
2.
Clin Pharmacol Ther ; 42(1): 113-8, 1987 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-3297467

RESUMEN

We studied the safety and efficacy of intravenous nicardipine alone and in combination with oral captopril. Sixteen patients with essential hypertension received a single oral dose of captopril, 50 mg, to be certain that excessive hypotension would not occur. Nicardipine was given intravenously as a 2 mg bolus, followed by an infusion at a rate designed to lower the supine diastolic blood pressure at least 10 mm Hg; then oral captopril, 50 mg, or placebo was given. The next week, nicardipine was again infused, but the alternate oral treatment was given. Intravenous nicardipine reduced blood pressure from 156 +/- 15/101 +/- 5 mm Hg (mean arterial blood pressure 120 +/- 6 mm Hg) to 140 +/- 11/88 +/- 4 mm Hg (mean arterial blood pressure 105 +/- 5 mm Hg). When captopril was added to nicardipine, the mean arterial blood pressure fell an additional 8 mm Hg but the heart rate did not increase. The combination of angiotensin-converting enzyme inhibition and calcium channel blockage produces additive antihypertensive effects without additional reflex tachycardia.


Asunto(s)
Captopril/uso terapéutico , Hipertensión/tratamiento farmacológico , Nicardipino/uso terapéutico , Administración Oral , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Captopril/farmacología , Quimioterapia Combinada , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Inyecciones Intravenosas , Persona de Mediana Edad , Nicardipino/sangre , Nicardipino/farmacología
3.
Clin Pharmacol Ther ; 43(5): 542-6, 1988 May.
Artículo en Inglés | MEDLINE | ID: mdl-3259170

RESUMEN

Ketorolac tromethamine, an analgesic agent with prostaglandin synthetase--inhibiting activity, is more active than aspirin in vitro in inhibiting collagen- or arachidonic acid-induced platelet aggregation. In this randomized, double-blind study, 26 volunteers received ketorolac, 30 mg intramuscularly four times a day for 5 days, and placebo, two capsules orally four times a day for at the last 2 study days. The effects of this treatment were compared with those of intramuscular placebo and oral aspirin, two 325 mg capsules, given on the same schedule to eight volunteers. Aspirin at a mean serum concentration of 84 micrograms/ml did not affect prothrombin time, partial thromboplastin time, platelet count, or bleeding time. Ketorolac produced a modest prolongation of the bleeding time, from 4.9 +/- 1.1 minutes (mean +/- SD) to 7.8 +/- 4.0 minutes (p less than 0.005). Ketorolac did not affect the prothrombin time or partial thromboplastin time but was associated with clinically insignificant change in the platelet count from 303 +/- 57 X 10(3)/m3 to 277 +/- 56 X 10(3)/mm3.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Hemostasis/efectos de los fármacos , Pirroles/farmacología , Tolmetina/farmacología , Trometamina/farmacología , Adulto , Aspirina/farmacología , Combinación de Medicamentos/efectos adversos , Combinación de Medicamentos/farmacología , Equimosis/etiología , Humanos , Inyecciones Intramusculares , Ketorolaco Trometamina , Persona de Mediana Edad , Dolor/etiología , Tolmetina/efectos adversos , Tolmetina/análogos & derivados , Trometamina/efectos adversos
4.
Cardiovasc Drugs Ther ; 4(2): 493-7, 1990 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2285632

RESUMEN

In 82 healthy normotensive and hypertensive subjects aged 19-79, blood pressure and heart rate were measured for 1 hour before and 2 hours after a meal. Mean blood pressure decreased from 147/93 to 139/83 mmHg supine and from 148/101 to 142/94 mmHg standing (all p less than .001). Older subjects had higher premeal blood pressures. There were significant correlations between age and the reductions in supine systolic and diastolic blood pressures and standing systolic blood pressure, i.e., older patients had greater reductions. However, after statistical correction for premeal blood pressure, there was no longer any significant relationship between age and the cardiovascular response to meals. The greater blood pressure reduction after meals in older patients may be due to decreased baroreflex sensitivity in association with higher arterial pressures. The changes in blood pressure due to meals may confound the diagnosis of hypertension and interfere with the interpretation of the response to antihypertensive treatment.


Asunto(s)
Envejecimiento/fisiología , Presión Sanguínea/fisiología , Ingestión de Alimentos/fisiología , Frecuencia Cardíaca/fisiología , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad
5.
Eur J Clin Pharmacol ; 35(1): 21-4, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-2975595

RESUMEN

The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients. For an 8 mg daily dose mean Cmax at steady-state for all patients was 108 ng/ml; the mean tmax was 1.8 h. The mean terminal elimination half-life was 22 h. The four tablets containing 1, 2, 4, or 8 mg of doxazosin were bioequivalent in delivering the 8 mg dose. In patients with mild to moderate hypertension, 26-day treatment with doxazosin resulted in blood pressure reduction of 10/7 mmHg in the supine and 13/18 mmHg in the standing position. Adverse effects were generally mild and of brief duration.


Asunto(s)
Antihipertensivos/uso terapéutico , Hipertensión/tratamiento farmacológico , Prazosina/análogos & derivados , Adulto , Antihipertensivos/efectos adversos , Antihipertensivos/farmacocinética , Presión Sanguínea/efectos de los fármacos , Doxazosina , Femenino , Semivida , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Prazosina/efectos adversos , Prazosina/farmacocinética , Prazosina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA